XML 78 R35.htm IDEA: XBRL DOCUMENT v2.4.0.8
Intangible Assets and Royalty Agreement (Details) (USD $)
 0 Months Ended 3 Months Ended 3 Months Ended 3 Months Ended 3 Months Ended 3 Months Ended 3 Months Ended 3 Months Ended 3 Months Ended 3 Months Ended 3 Months Ended 3 Months Ended
Mar. 31, 2008
Jan. 29, 2007
Jun. 30, 2013
Dec. 31, 2012
Jun. 30, 2013
Trade Names and Trademarks [Member]
Dec. 31, 2012
Trade Names and Trademarks [Member]
Jun. 30, 2013
In Process Research and Development, Other [Member]
Dec. 31, 2012
In Process Research and Development, Other [Member]
Jun. 30, 2013
License-Shriners Hsp for Children & USF Research [Member]
Dec. 31, 2012
License-Shriners Hsp for Children & USF Research [Member]
Jun. 30, 2013
License - SaluMedica LLC Spine Repair [Member]
Dec. 31, 2012
License - SaluMedica LLC Spine Repair [Member]
Jun. 30, 2013
License - Polyvinyl Alcohol Cryogel [Member]
Dec. 31, 2012
License - Polyvinyl Alcohol Cryogel [Member]
Jun. 30, 2013
Customer Relationships [Member]
Dec. 31, 2012
Customer Relationships [Member]
Jun. 30, 2013
Supplier Relationships [Member]
Dec. 31, 2012
Supplier Relationships [Member]
Jun. 30, 2013
Patents and Know-How [Member]
Dec. 31, 2012
Patents and Know-How [Member]
Jun. 30, 2013
Micronized Processing Know-How [Member]
Dec. 31, 2012
Micronized Processing Know-How [Member]
Jun. 30, 2013
Licenses and Permits [Member]
Dec. 31, 2012
Licenses and Permits [Member]
Jun. 30, 2013
Patent Application Cost [Member]
Dec. 31, 2012
Patent Application Cost [Member]
Finite-Lived Intangible Assets [Line Items]                                                    
Weighted Average Amortization Lives                 10 years [1]   10 years [2]   10 years [3]   14 years [4]   14 years [4]   14 years [4]   14 years [4]   3 years [4]   17 years [5]  
Gross Carrying Value     $ 16,070,200 $ 17,526,000         $ 996,000 [1] $ 996,000 [1] $ 1,547,324 [2] $ 2,399,000 [2] $ 1,720,181 [3] $ 2,667,000 [3] $ 3,520,000 [4] $ 3,520,000 [4] $ 241,000 [4] $ 241,000 [4] $ 5,530,000 [4] $ 5,530,000 [4] $ 2,160,000 [4] $ 2,160,000 [4] $ 13,000 [4] $ 13,000 [4] $ 342,695 [5] $ 0 [5]
Accumulated Amortization     (5,378,990) (4,848,756)         (637,433) [1] (587,633) [1] (1,547,324) [2] (1,547,324) [2] (1,287,824) [3] (1,223,561) [3] (628,572) [4] (502,857) [4] (43,036) [4] (34,428) [4] (987,500) [4] (790,000) [4] (231,428) [4] (154,286) [4] (10,833) [4] (8,667) [4] (5,040) [5] 0 [5]
Acquisition price, one-time license fee   100,000                                                
Impairment Adjustment       (1,798,495)               (851,676) [2]   (946,819) [3]                        
Net carrying value, Total     10,691,210 10,878,749         358,567 [1] 408,367 [1] 0 [2] 0 [2] 432,357 [3] 496,620 [3] 2,891,428 [4] 3,017,143 [4] 197,964 [4] 206,572 [4] 4,542,500 [4] 4,740,000 [4] 1,928,572 [4] 2,005,714 [4] 2,167 [4] 4,333 [4] 337,655 [5] 0 [5]
Shares issued for intangibles (in shares)   1,120,000                                                
Value of shares issued for intangibles   896,000                                                
Maximum time of approval   30 days                                                
Contingent payments to licensor   200,000                                                
Contingent royalty to be paid to licensor (in hundredths)   3.00%                                                
Acquisition price of asset, shares issued (in shares) 400,000                                                  
Acquisition of asset, value of shares issued 2,596,000                                                  
Number of shares issuable upon meeting certain milestones (in shares) 600,000                                                  
Contingent payments to licensor, shares issued (in shares) 100,000                                                  
Contingent payment to licensor, value of shares issued 71,000                                                  
Indefinite-lived Intangible Assets [Line Items]                                                    
Weighted average useful life Indefinite lived         indefinite [4]   indefinite [4]                                      
Gross Carrying Value         1,008,000 [4] 1,008,000 [4] 25,000 [4] 25,000 [4]                                    
Accumulated Amortization         0 [4] 0 [4] 0 [4] 0 [4]                                    
Net Carrying Value         1,008,000 [4] 1,008,000 [4] 25,000 [4] 25,000 [4]                                    
Intangible assets, gross carrying value     17,103,200 18,559,000                                            
Impairment Adjustment       (1,798,495)                                            
Accumulated Amortization     (5,378,990) (4,848,756)                                            
Intangible assets, net carrying value     11,724,210 11,911,749                                            
Estimated future amortization expense [Abstract]                                                    
2013     535,266 [6]                                              
2014     1,066,205                                              
2015     1,044,151                                              
2016     997,156                                              
2017     906,960                                              
Thereafter     $ 6,141,472                                              
[1] On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. The acquisition price of this license was a one-time fee of $100,000 and 1,120,000 shares of common stock valued at $896,000 (based upon the estimated fair value of the common stock on the transaction date). Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor. Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products
[2] License from SaluMedica, LLC (SaluMedica) for the use of certain developed technologies related to spine repair. This license was acquired through the acquisition of SpineMedica Corp. In September 2012, the cost of this license was deemed to be impaired and reduced to its fair value
[3] On March 31, 2008, the Company entered into a license agreement for the use of certain developed technologies related to surgical sheets made of polyvinyl alcohol hydrogel. The acquisition price of the asset was 400,000 shares of common stock valued at $2,596,000 (based upon the closing price of the common stock on the transaction date). The agreement also provides for the issuance of an additional 600,000 shares upon the Company meeting certain milestones related to future sales. On December 31, 2009, the Company completed the sale of its first commercial product and met its first milestone under this agreement. As a result, the Company issued an additional 100,000 shares of common stock to the licensor valued at $71,000. In September 2012, the cost of the license was deemed to be impaired and reduced to its fair value. At June 30, 2013 and December 31, 2012, there are no additional amounts accrued for this obligation due to its contingent nature
[4] On January 5, 2011, the Company acquired Surgical Biologics, LLC. As a result, the Company recorded intangible assets for customer and supplier relationships, patents and know-how, licenses/permits, trade names and trademarks and in-process research and development
[5] Capitalized external legal and other registration costs in connection with internally developed tissue based patents.
[6] Estimated amortization expense for the year ending December 31, 2013 includes only amortization to be recorded after June 30, 2013.